For the Skin Cancer Prevention Study Group
Background: Human evidence that ionizing radiation is carcinogenic first came from reports of nonmelanoma skin cancers (NMSCs) on the hands of workers using early radiation devices. An increased risk of NMSC has been observed among uranium miners, radiologists, and individuals treated with x rays in childhood for tinea capitis (ringworm of the scalp) or for thymic enlargement; NMSC is one of the cancers most strongly associated with the atomic bombing of Hiroshima and Nagasaki. Although exposure to ionizing radiation is a known cause of NMSC, it is not yet clear whether therapeutic radiation causes both major histologic types of NMSC, basal cell carcinoma (BCC) and squamous cell carcinoma (SCC). Additionally, the potentially modifying effects, such as latency, age when treated, and type of treatment, are not well understood. Purpose: We investigated the relative risks of BCC and SCC associated with previous radiation therapy and evaluated these risks in relation to age and time since initial treatment and the medical condition for which radiation therapy was given. Methods: The study group comprised individuals diagnosed with at least one BCC or SCC from January 1980 through February 1986, who were recruited to participate in a skin cancer prevention trial designed to test whether oral P-carotene supplementation would reduce the risk of new NMSCs. Patients were identified through the dermatology and pathology records of academic medical centers in Hanover, NH; Los Angeles, CA; San Francisco, CA; and Minneapolis, MN. Each participant completed a questionnaire detailing lifetime residence, pigmentary characteristics, occupational and recreational sun exposure, and history of radiation therapy. At enrollment, a study dermatologist assessed skin type (tendency to burn or tan) and extent of actinic skin damage. Participants were followed with an annual dermatologic examination for an average of 4 years. Of the 5232 potentially eligible individuals, 1805 were enrolled in the trial. We excluded 112 patients who reported previous radiation therapy for skin cancer only and three with missing information on whether they were ever treated with radiation therapy, leaving 1690 patients for the analysis. Approximately 4% of the patients died or discontinued participation for other reasons during each study year. We examined time to occurrence of first new histopathologically confirmed BCC and SCC during the follow-up period in relation to history of radiation therapy (for reasons other than NMSC) using a proportional hazards model. A multiple end points survival model was used to compare the rate ratios (RRs) for BCC and SCC. We also used a longitudinal method of analysis to compute the RR of total new BCC and SCC tumors per person per study year associated with radiation therapy. Using this method, we additionally assessed the potential modifying effects of age at treatment, latency, and type of therapy. All P values were derived from two-sided statistical tests of significance. Results: Among the participants we studied, 597 developed a new BCC (n = 1553 tumors) and 118 developed a new SCC (n = 179 tumors). The time to first new BCC, but not SCC, was associated with prior radiation therapy (RR = 1.7; 95% confidence interval [CI] = 1.4-2.0 and RR = 1.0; 95% CI = 0.6-1.7, respectively; P = .03 for the difference between the RRs). The RR of total BCC tumors was slightly higher (RR = 23; 95% CI = 1.7-3.1), but it was still unity for SCC (RR = 1.0; 95% CI = 0.5-1.9). BCC risk appeared to increase with younger age at exposure and time since initially treated, although these effects were only marginally statistically significant (P for trend = .06 and .07, respectively). Also, risk of BCC was more strongly related to treatment for acne (RR = 33; 95% CI = 2.1-5.2) than other conditions. Conclusions and Implications: Our data suggest that exposure to therapeutic radiation is associated with BCC but not with SCC. Several aspects of the relationship of ionizing radiation exposure to the risk for skin cancer are not yet fully understood and warrant continued investigation. [J Natl Cancer Instl996; 88:1848-53] The first human evidence that ionizing radiation is carcinogenic came from reports of nonmelanoma skin cancers (NMSCs) on the hands of workers using early radiation devices [reviewed in (7) ]. Since that time, an increased risk of NMSC has been observed in several radiation-exposed groups, including uranium miners (2), radiologists (3), and individuals treated with x rays in childhood for tinea capitis (4, 5) or for thymic enlargement (6) . NMSC is one of the cancers most strongly associated with the atomic bombing of Hiroshima and Nagasaki (7) . Despite the consistent findings of increased NMSC risk, it is not known whether therapeutic radiation causes both major histologic types of NMSC, basal cell carcinoma (BCC) and squamous cell carcinoma (SCC). Also, the potentially modifying effects, such as latency, age when treated, and type of treatment, are not well understood. Therefore, we investigated the relative risks of BCC and SCC associated with previous radiation therapy and evaluated these risks in relation to age and time since initial treatment and the medical condition for which radiation therapy was given.
Subjects and Methods
A detailed description of the design of the original trial and study population is provided elsewhere (S). Briefly, individuals diagnosed with at least one BCC or SCC from January 1980 through February 1986 were recruited to participate in a skin cancer prevention trial designed to test the efficacy of 50 mg per day of oral ^-carotene in reducing the risk of new NMSCs. Patients were identified through the dermatology and pathology records of academic medical centers in Hanover, NH; Los Angeles, CA; San Francisco, CA; and Minneapolis, MN. A total of 5232 individuals were potentially eligible and, of these, 1805 were enrolled in the trial. Patients who were 85 years of age or older, women of childbearing potential, and those who had a history of xeroderma pigmentosum, basal cell nevus syndrome, known arsenic exposure, or a medical condition that would limit their participation in the trial were not enrolled. Informed consent was obtained before enrollment using a protocol approved by the institutional review boards of the respective institutions, each of which had an appropriate assurance filed with and approved by the U.S. Department of Health and Human Services.
Before being randomly assigned, each study participant completed a questionnaire, which included questions regarding lifetime residence, pigmentary characteristics (e.g., eye and hair color), ethnicity, occupational and recreational sun exposure, and history of cigarette smoking. Participants were also asked if they had ever had radiation therapy, with a clarifying statement that the question was specifically addressing therapy, not diagnostic tests. Those participants who responded positively were asked to note the year they were first treated, the conditions for which treatment was given, and the parts of the body receiving treatment (classified as face and head, trunk (torso), arms/hands, and legs/feet). At enrollment, each participant was examined by a study dermatologist who assessed skin type (tendency to bum or tan) and extent of actinic skin damage (9).
Participants were followed with an annual dermatologic examination for an average of 4 years. At each yearly examination, participating dermatologists removed all lesions suspected of being cancerous and sent the biopsy specimens for re-review by the study dermatopathologisL Approximately 4% of the patients dropped out each year because of death, illness, or refusal to return for the annual visit (8). For the analyses reported here, we excluded 112 patients who reported previous radiation therapy for skin cancer only and three with missing information on whether they had ever been treated with radiation therapy; we used data from the remaining 1690 patients.
Statistical Analysis
We analyzed the data both as time to first event and as total number of events per person per year.
We first calculated rate ratios (RRs) and 95% confidence intervals (CIs) using a proportional hazards model with time to first new NMSC as the study end point (/0). To adjust for the effects of potentially confounding variables, previously identified skin cancer risk factors (age, sex, study center, and extent of actinic skin damage) were included as covariates in all models. We used a multiple end points survival analysis to determine whether exposure to therapeutic radiation differed between BCC and SCC (//). This model is an extension of the Cox proportional hazards model, with each histologic type (BCC and SCQ as separate strata. Proportional hazards are preserved within strata, and the model accounts for correlations among events for the same individuals.
Since some patients developed more than one new BCC or SCC during the follow-up period, we also examined the overall rate of new BCC and SCC occurrences per person per study year using a method for the analysis of longitudinal count data (12) . This method accounts for correlations among events within patients and patient heterogeneity in event rates. We performed further analyses of BCC using this method, but there were insufficient numbers of SCC cases to permit a more detailed analysis of this type of skin cancer. Age at exposure, years since first treated, and medical condition for which ionizing radiation therapy was given were each examined in relation to risk of new BCC occurrences. We also evaluated the RR of BCC at specific anatomic sites (head and neck, trunk, or limbs) associated with radiation exposure to these sites (grouped as face and head, trunk, and limbs). In these analyses, we evaluated the site of the first BCC diagnosed during the follow-up period. Individuals who received radiation therapy involving more than one area were excluded from the sitespecific analyses. All P values were derived from two-sided statistical tests of significance.
Results
Participants ranged in age from 27 to 84 years (mean, 62.8 years; standard deviation = 10.1 years), and 31% were women. Overall, 262 (15.5%) patients reported having undergone radiation therapy (excluding those who reported radiation therapy for NMSC). A higher percentage of women than men reported a history of radiation therapy, as did participants from the Los Angeles and Minneapolis centers compared with those from San Francisco and Hanover. There was no consistent relationship between radiation therapy and age at study entry or extent of actinic skin damage (Table  1) . Acne was the predominant condition for which radiation therapy was given (Table 2) . Therapy for reasons other than cancer occurred almost entirely before 1960 (Table 2) .
A total of 597 study participants developed 1553 new BCCs, and 118 developed 179 new SCCs. These totals include 73 participants who developed both an SCC and a BCC during the follow-up period. The rate of time to first BCC was higher among those who reported radiation therapy than among those who reported no prior therapy (RR = 1.7; 95% CI = 1.4-2.0). In contrast, radiation therapy was not associated with new SCCs (RR = 1.0; 95% CI = 0.6-1.7). The difference between the relative risk for BCC and SCC was statistically significant (P = .03) in the multiple end points analysis. There was no evidence that the relative risks varied over time (i.e., that the hazards were nonproportional). Patients who reported radiation therapy had a substantially higher overall frequency of new BCC tumors than those who reported no prior therapy (447 events per 1146 person-years among the radiation treated and 1106 events per 6056 person-years in the unexposed; RR = 2.3; 95% CI = 1.7-3.1). Again, the relative rate of total new SCC occurrences was not elevated (24 events per 1146 person-years among the radiation treated and 155 events per 6056 personyears in the unexposed; RR = 1.0; 95% CI = 0.5-1.9).
For BCC, the relative rates were the highest among those treated at a younger age (Table 3) . For example, the relative rate for those treated before age 20 years was 2.7 (95% CI = 1.7-4.4) and after age 40 years was 1.7 (95% CI = 1.0-2.8) (Table 3) ; the linear trend in the relative rates was marginally significant (P for trend = .06). The risk of BCC also appeared to increase with time since exposure and was the highest 20 or more years after exposure (RR = 2.6; 95% CI = 1.5-4.3) (Table 3) ; the overall test for trend was of borderline significance (P for trend = .07). The risk for new BCC differed by reason for treatment and was greatest for those who had radiation therapy for acne (RR = 3.3; 95% CI = 2.1-5.2) (Table 3) .
When we examined specific anatomic sites of exposure, we found that those who received radiation therapy to the face and neck had an increased rate of BCC of the head and neck, trunk, and limbs (Table 4 ). The elevated rate of BCC of the trunk and limbs appeared to be largely confined to radiation therapy to either of those sites (Table 4) . •Excludes 112 patients who had received previous radiation therapy for skin cancer and three who were missing information on whether they had ever received radiation therapy. tPercentages equal patients who had received pnor radiation therapy/total number of patients (e.g., 32/174 = 18%).
Discussion
With the use of data from a routinely monitored cohort of skin cancer patients, we found that prior radiation therapy was related to an increased risk of developing a new BCC. The RR was higher for total number of BCC tumors than for time to first BCC, suggesting that there may be a greater risk associated with multiple BCC occurrences. We did not find any evidence of an elevated risk of SCC associated with radiation therapy; however, a relative risk of less than 2 may have escaped detection in our study, since there were relatively fewer SCC occurrences. Radiation therapy for acne, in particular, was associated with about a threefold risk of a new BCC. There were only modest or no appreciable increases in BCC risk associated with treatment for other benign dermatologic conditions, cancer, or all other conditions combined, but these conditions were reported less frequently by our subjects.
In a previous analysis of this same population, we found distinct patterns of risk factors for BCC and SCC (9) . Our present findings also suggest that these tumors differ with respect to the effects of ionizing radiation exposure. In a cohort study (5) of individuals irradiated for tinea capitis in Israel, the overall relative risk of head and neck skin cancers was 4.2 and for BCC alone was 4.9; there were only a few occurrences of SCC. Similarly, in a study of x-ray therapy for tinea capitis conducted in New York, there was a roughly sixfold risk of head and neck BCC, and no SCCs were observed in the cohort (4). A stronger excess risk for BCC than SCC was also noted among atomic bomb survivors, although the actual risk estimates were not presented (7) .
There is evidence that the risk of skin cancer may be higher among those who received radiation therapy at an earlier age. Among Hiroshima and Nagasaki atomic bomb survivors, little to no discernible excess risk of skin cancer was observed for those who were aged 40 years or older at detonation (7). Ron et al. (5) found a linear decrease in the relative risk of head and neck skin cancer with increasing age at irradiation for tinea capitis, and in this study, treatment occurred solely during childhood. Our data corroborate these findings in that we also observed that the risk of BCC associated with exposure tended to be greatest in those exposed early in life.
A relatively long latency period is suspected for radiation-induced cancers, but the latency period for NMSCs is not yet known. Shore et al. (4) found little or no excess NMSC risk in the first 20 years after irradiation. In contrast, the risk of skin cancer was not associated with time since detonation of the atomic bomb (7) or time since treatment of tinea capitis (5) . In our data, risk appeared to become •Includes the four patients who were treated for more than one condition. Twelve patients were missing information on reason for treatment, and one additional patient was missing information on year of treatment.
tPercentage of patients treated for specified conditions (eg., 114/253 = 45.1 %). (23) 1106 (473) 41 (15) 167 (50) 228 (56) 1106 (473) 259 (62) 76 (24) 23 (8) 69 ( •Rate ratio (RR) and confidence interval (CI) from longitudinal model adjusted for age (continuous), sex, study center (San Francisco, Los Angeles, Hanover, and Minneapolis), and actinic skin damage (mild, moderate, and severe). Thirteen individuals who were missing data on actinic skin damage are excluded from this analysis.
tExcludes five individuals with missing information on when they were treated. Excludes 12 individuals with missing information on reason for treatment and four who were treated with x rays for more than one condition. §Radiation therapy for cancer, excludes treatment for nonmelanoma skin cancer.
greater with increasing time from exposure. However, we were unable to estimate the time from exposure to first NMSC occurrence because all of our study participants had at least one NMSC prior to study entry. Moreover, it is difficult to separate the effects of latency from the effects of age at treatment and dose and type of radiation therapy received. Delineation of these effects will likely require greater numbers of exposed and diseased individuals than any studies conducted to date have provided, including ours, and more precise treatment information (i.e., dose) than was available on our cohort.
An increased risk of skin cancer has been observed with occupational, therapeutic, and atomic bomb exposure to ionizing radiation (2) (3) (4) (5) (6) (7) (13) (14) (15) , but there are also reports of no increase in risk of skin cancer mortality following x-ray therapy for ankylosing spondylitis (16) and among uranium miners (17) . These discordant results may partly reflect the use of skin cancer mortality as the study end point; NMSCs are rarely fatal, and mortality figures do not accurately reflect skin cancer incidence. A cohort study of women treated for cervical cancer did not find an increased risk of NMSC occurrence after radiation therapy (18) . A large number of NMSCs were identified in this study, although the ascertainment of new skin cancers involved use of cancer registries that do not routinely collect data on NMSCs.
It is possible that UV light enhances the risk associated with radiation exposure, and the absence of an excess risk in patients with cervical cancer may be due to the lack of sunlight exposure to the pelvic region. Stern et al. (79) found that individuals treated with ionizing radiation had a higher risk of skin cancer following psoralen and ultraviolet A therapy than those who had not previously received radiation therapy. In another report (5), •Rate ratio (RR) and confidence interval (CI) from longitudinal model adjusted for age (continuous), sex, study center (San Francisco, Los Angeles, Hanover, and Minneapolis), and actinic skin damage (mild, moderate, and severe). The 13 individuals who were missing data on actinic skin damage are excluded from this analysis. Also excluded are the two individuals who reported radiation therapy but who did not indicate the site at which they were treated and 36 individuals who were treated at more than one site. tRadiation therapy to the head and face only (N = 224 BCC tumors). Radiation therapy to the trunk only (N = 93 BCC tumors). §Radiation therapy to the limbs only (N = 38 BCC tumors).
individuals immigrating from Asian or African countries had a lower relative risk of NMSC associated with radiation therapy for tinea capitis than did other Israelis, suggesting that skin types more susceptible to UV carcinogenesis may have been more susceptible to ionizing radiation. In contrast, a twofold excess risk of skin cancer was observed in a Danish cohort study of patients with testicular cancer, and the investigators hypothesized that this was most likely due to the use of radiotherapy; in these patients, the treatment field would have included areas with minimal sun exposure (20) . In our study, the BCC risk associated with radiation therapy did not appear to be confined to anatomic sites more likely exposed to the sun and did not differ by skin type (data not shown). Nonetheless, it is possible that some patients are genetically susceptible to radiation-induced tumors and that this susceptibility is not reflected by the skin type assessment in our data. The possibility that acne or treatment for acne rather than the x-ray therapy increased the risk of BCC in our study is unlikely, and the one study (21) that examined this issue found a reduced risk of BCC in relation to acne. Most of our patients were treated before the 1960s, at a time when treatment involved relatively low-energy orthovoltage x-ray equipment. Superficial irradiation for benign skin conditions such as acne involved 60-100 kV, with a total dose of about 1400 rad (22) . Shorter wavelength Grenz ray therapy was also available but rarely used in the United States, since it was not found to be effective (23) . More recent treatment devices deliver much higher energy beams but are designed to minimize skin exposure; thus, the results of our analyses may not be generalizable to patients treated in more recent years with more modern equipment. Our findings of an elevated BCC rate at reportedly untreated areas may reflect unintentional exposure to these sites, particularly when the harmful effects of radiation therapy were less known. While it also possible that our findings are attributable to increased detection of skin cancers among those known to be exposed to radiation therapy, all patients underwent a complete dermatologic assessment annually, and every lesion suspected of being cancerous was removed from each of them. Lack of adequate control for potentially confounding factors is another plausible source of bias, although our analyses were adjusted for the major NMSC risk factors previously observed in this cohort (9) .
A major limitation of our data is that the assessment of radiation therapy was based on patients' recall. The validity of recall of radiation therapy is not known, but self-reported data on diagnostic x rays and other medical exposures are often reliable (24, 25) . To minimize misclassification, our questionnaire specifically stated that the question was referring to radiation therapy, not diagnostic tests. Still, patients could confuse other forms of treatment (e.g., UV-light therapy) or diagnostic procedures with radiation therapy. The conditions for which subjects reported radiation therapy corresponded with the time period during which the therapies were used, suggesting that this was not a major source of misclassification in our data ( Table 2) . We were not, however, able to evaluate the dose of radiation therapy received, an issue for which further studies are needed.
Our findings are based on a large number of study subjects, routinely followed with annual dermatologic examinations. Thus, we had both consistent and complete ascertainment of skin cancers during the follow-up period. To be eligible for the study, we required participants to have had at least one prior skin cancer, and this fact may limit the generalizability of our findings. In a previous analysis (9) of this population, the magnitude of the relative risks associated with subsequent skin cancers was similar to those previously reported for skin cancer in the general population. In the present analysis, the relative risk estimate for BCC associated with radiation therapy remained significantly elevated, even after adjustment for the number of prior BCCs; after adjustment for prior SCC, the risks for SCC were still close to 1. We did not adjust for number and type of prior skin cancers in our main analysis, since these factors likely reflect the causal effects of radiation therapy themselves (26) .
In summary, our data indicate that patients with skin cancer who have a history of ionizing radiation therapy are at a significantly elevated risk of developing a new BCC. This finding, combined with the observed prevalence of radiation therapy history in our cohort, suggests that an important number of BCC occurrences in the United States may be a result of prior radiation therapy. Several aspects of the relationship of ionizing radiation exposure to the risk of skin cancer are not yet fully understood and warrant continued investigation.
